Tuesday, April 29, 2025

Latest

Moderna To Construct Manufacturing Facility In Australia Under New Strategic Partnership

Moderna Inc (NASDAQ: MRNA) is officially going to the land down under. The company late last night announced that it has finalized a strategic partnership with the Australian federal government that will see a manufacturing facility for mRNA vaccines established within the country.

The strategic partnership is said to be for an initial ten year period, with construction to begin on the facility by the end of this year. It is currently anticipated that construction will be completed by the end of 2024, at which time the facility is expected to become operational, subject to regulatory approvals.

The new facility is to be constructed in Melbourne, Australia, and is to provide the country with locally manufactured mRNA vaccines intended to be used against COVID-19, seasonal influenza, RSV, and other respiratory viruses. Current capacity plans call for up to 100 million mRNA vaccine doses to be produced on an annual basis.

Reciprocally, the company will also support mRNA research and development within the country, and has agreed to establish a regional research centre for tropical diseases and respiratory medicines.

It is currently expected that the move will assist in developing a “world-class mRNA industry” within the country.

Separately, the firm this morning indicated it is moving forward with regulatory submissions for vaccinations in children under 6 against COVID-19. The firm has also received a total of $21 billion in advance purchase agreements for vaccines in its current portfolio.

“We are focused on unmet vaccine needs for respiratory viruses, latent viruses, and persistent global health threats. Importantly, we also continue to advance a range of COVID-19 vaccine options for adults, adolescents, and pediatric populations,” said CEO Stephen Bancel

Moderna last traded at $178.73 on the Nasdaq.


Information for this briefing was found via Moderna and the companies mentioned. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Leave a Reply

Video Articles

Bell Q3 Earnings: Massive Impairments. Guidance Cuts. A Mess.

Alamos Gold Q3: Record Revenue & Production Amid Rising Costs

The Junior Mining Market Is Back

Recommended

Germany Looks To Modernize Military Recruitment But Stops Short of Conscription

First Majestic Silver Posts Topline Revenue Of $146.1 Million In Q3 2024

Related News

Moderna Shares Jump After Announcing Q4 2021 Earnings, US$19 Billion Advanced Sales

Moderna Inc (Nasdaq: MRNA) announced this morning its Q4 and full-year 2021 earnings. The vaccine manufacturer...

Thursday, February 24, 2022, 10:51:00 AM

Moderna Shares Soar As Company Announces $3 Billion Stock Buyback

Moderna Inc (NASDAQ: MRNA) shares on Wednesday soared as high as 17% after it announced...

Thursday, August 4, 2022, 08:26:43 AM

No, The CEO Of Moderna Didn’t Just Dump $400 Million In Shares

The trouble with social media, is that it’s a big game of telephone. One individual...

Sunday, February 13, 2022, 02:50:29 PM

New COVID Variant Sweeps China, Is North America Next?

Remarkably, the world could be facing another bout with COVID this year, and with negative...

Thursday, May 25, 2023, 07:35:00 AM

Moderna and Merck & Co: mRNA Cancer Vaccine Shows “Highly Encouraging Results,” Shares Rise

On Tuesday, Moderna (NASDAQ: MRNA) announced that their personalized cancer-vaccine program was successful in a...

Wednesday, December 14, 2022, 01:06:00 PM